An improved approach for drug discovery including cellular iPS cell-based 2D models and cerebral organoids. The implementation of iPS cell-derived 2D and 3D culture systems could improve several aspects of the drug discovery pipeline in psychopharmacology. Based on prestratified patient cohorts (either by clinical manifestation or by research domain criteria), iPS cell-based disease models should help to further stratify patients according to molecular alterations referred to as  "molecular biotypes." Starting from those molecular biotypes, iPS cell-based target identification using 2-dimensional cultures followed by target validation applying cerebral organoids should minimize false positives processed via the drug discovery pipeline. Finally, the improved drug specificity could feed back into the advanced patient stratification eventually leading  to better medical treatment specific to the molecular biotypes.
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Introduction 
=============

Psychiatric diseases are devastating disorders of complex and diverse etiology. The highly polygenic disease architecture and the variable genetic, epigenetic, and environmental factors that contribute to the manifestation of mental diseases have made it challenging to understand their development and pathophysiology. ^[@ref1]^ Genome-wide association studies of large cohorts of individuals with neuropsychiatric disorders have led to a wealth of data on the genetics of these diseases. The proportion of patients in whom candidate causal or contributing genetic variants are identified is, however, still very limited. Even though medication is available to relieve symptoms and disruptive behaviors, there are often no effective pharmacological treatments to improve the core deficits. New drug development has stalled due to the lack of well-defined molecular targets, our restricted understanding of the origin and the biological mechanism of psychiatric disorders, and the limitations of current research models to investigate biological processes within the human brain under healthy and pathologic conditions. ^[@ref2]^ Thus far, animal models such as mice have been used to provide behavioral and molecular readouts, which allowed specification of the role of specific pathways in psychopathology. However, animal models have several limitations: they cannot fully reproduce the plethora of psychiatric symptoms observed in patients, nor can they recapitulate the complex structure and function of human brains. ^[@ref3]^ Most human post-mortem specimens represent a late stage or end point of the disease and thus cannot provide information about how these disorders develop. Moreover, the pharmacological treatment and the comorbidities of psychiatric disorders represent confounding factors that make it difficult to obtain a clear and uniform readout from post-mortem studies. ^[@ref4]^ Lastly, biopsies of brain tissue are an invasive approach associated with several ethical concerns, which---considering the low yield and the impossibility of expanding post-mitotic neurons in vitro---do not represent a powerful option. 

In this context, the advent of reprogramming technology and the potential to differentiate induced pluripotent stem cells (iPS cells) into almost any desired cellular subtype has revolutionized modern biomedicine and provides a new platform to study human pathologies in vitro. ^[@ref5]^ Merging iPS cell technology with human genetics offers the great opportunity to generate unique biological information about the molecular mechanisms involved in the pathophysiology of mental illnesses and to explore new drug targets. As reprogrammed cells carry the genetic background of a patient, they represent a valid platform for identifying genetic predictors of drug responses and associating cellular abnormalities with clinical phenotypes in a human context. In recent years, iPS cell-based models derived from psychiatric patients have recapitulated the key molecular features of psychiatric disorders such as schizophrenia (SCZ), autism spectrum disorders (ASDs), and bipolar (BP) disorders ^[@ref2]^ , ^[@ref6]^ and have led to the first psychopharmacological screens. ^[@ref7]^ - ^[@ref9]^ However, classical iPS cell models based on homogeneous cellular populations grown in the culture dish neglect the fact that the human brain is an integrated 3-dimensional (3D) tissue structure composed of multiple cell types and extracellular matrix. In this context, the dimensional complexity of in vitro models has been increased with the generation of cerebral organoids derived from iPS cells. These organoids allow us for the first time to model the 3D structure, organization, composition, and connectivity of the human brain ^[@ref10]^ and thus open up the possibility of studying complex human brain development and pathology outside the human body. Cerebral organoids resemble the early developing human brain also with respect to gene expression programs ^[@ref11]^ ; they exhibit human specific cellular diversity, 3D organization, histological layers, and migration patterns (reviewed in ref 12). Today, several protocols to generate standardized and even region-specific brain organoids are available representing for instance the dorsal and/or ventral telencephalon, the midbrain, the hippocampus, or the cerebellum. ^[@ref13]^ - ^[@ref17]^ With the advances in cell culture techniques, human cerebral organoids have become an integral part of cell-based disease modeling of the brain (reviewed in ref 11) and it can be assumed that this pivotal role will even increase in the future. In this review we will summarize the most significant findings obtained with iPS cell-based models of psychopathologies and will discuss how 2D and 3D models will potentially revolutionize psychopharmacology; both form an experimental model point of view as well as in the translational drug development pipeline.  

IPS cell-based psychopharmacology 
==================================

During the last decade, multiple psychiatric diseases have been successfully translated to iPS cell-based in- vitro modeling, investigating alterations associated with these disorders at a cellular or network level. Initially, most researchers concentrated on those few known and well-described copy number variations or mutations with high penetrance. In more recent years an increasing number of studies have started to investigate sporadic, complex, and polygenic cases of mental disease (for an overview of published iPS cell-based models of mental disorders, see *Table I* ). IPS cell-based neuropharmacology still remains in its infancy, with most neuropharmacological interventions being based on standard clinical pharmacological intervention. Still, interesting observations occur from those studies linking, for instance, clinical drug response to molecular alterations in cellular models. With the increasing number of measurable and quantifiable phenotypes described in cellular disease models the way will be paved for more unbiased pharmacological approaches which may eventually lead to the identification of new classes of psychopharmacological compounds and drugs. In the following paragraphs, we will concentrate on those iPS cell-based models for psychiatric disease in which pharmacological interventions were applied. For a more complete overview of iPS cell-based models of psychiatric disorders we refer to the excellent and comprehensive reviews published on this topic. ^[@ref2]^ , ^[@ref3]^ , ^[@ref10]^  

Schizophrenia 
==============

With a prevalence of almost 1% of the population, ^[@ref18]^ schizophrenia (SCZ) is one of the most frequent major psychoses. It is a highly polygenic psychiatric disorder characterized by a complex and variegated symptomatology. The molecular and cellular defects that contribute to disease initiation and/or progression are, however, still largely unknown. The first detailed characterization of iPS cell-derived neurons from schizophrenic patients was largely based on two families with strong familial history indicating an underlying genetic alteration with high penetrance. Indeed, genetic characterization of these patients revealed that one family harbored multiple copy number variations (CNVs) in schizophrenia-associated genes such as a deletion in the *NRG3* gene. This led to strong reduction of *NRG3* expression which was, very interestingly, also found in the other family even though without a clear genetic link. *NRG3* is involved in multiple processes during brain development and synaptic function. Neuronal cultures derived from these patients exhibited some striking defects in the maturity- and activity-independent synaptic transmission of a neurotropic virus, an epiphenomenon which indicates defects in synaptic assembly. ^[@ref8]^ Interestingly, the researchers observed that the antipsychotic drug loxapine was able to alleviate the defects in virus spreading which was associated with an increase in *NRG1* expression. Other antipsychotics such as clozapine, olanzapine, risperidone, and thiorizadine had no effect on the observed phenotype indicating a heterogenous and complex action of loxapine besides dopamine (D1, D2, D4) receptor antagonism. The authors also identified alterations in Wnt signaling which was further addressed in a subsequent study using neural precursors generated from the same iPS cell lines. This study also identified an increased susceptibility of the cells to redox challenges as well as a defect in progenitor cell migration. In contrast to the synaptic virus spreading phenotype, loxapine treatment did not result in any improvement of the observed alterations. ^[@ref19]^ A more recent study focused on STEP61, a brain-specific phosphatase involved in the regulation of synaptic function, which was upregulated in iPS cell-derived telencephalic excitatory neurons from two SCZ patient cohorts. STEP61 overactivation induces an increased internalization of NMDAR receptors, thus altering the inhibitory/excitatory balance at synaptic level. Of note, the antipsychotics loxapine and clozapine both normalized the activity of the phosphatase. ^[@ref20]^ Considering the impairment of the GABAergic system in the etiology of SCZ, in another study, authors derived a homogeneous culture of cortical interneurons from 14 patients in treatment with clozapine. SCZ interneurons showed decreased levels of different protocadherins, a result in line with studies in animal models and post mortem specimens. The dysregulated protocadherin-pathway resulted in an impairment in dendritic arborization that was corrected by phosphokinase C inhibitor treatment. ^[@ref21]^  

Autism 
=======

ASDs are neurodevelopmental disorders with a complex genetic background and characterized by a plethora of symptoms related to sociability and intellectual disabilities. ^[@ref22]^ Considering the polygenic origin of ASD, increasing scientific attention has recently been focused on iPS cells. Indeed, this approach allows investigation of the complex in vitro dynamics and sheds light on the mechanisms underpinning the different manifestation of ASD. With respect to neuropharmacological intervention, Marchetto and collaborators found an increased cellular proliferation associated with the increased activity of the β-catenin/BRN2 cascade in neural progenitors obtained from a cohort of idiopathic autistic patients with clinical signs of early-age macrencephaly. Neurons derived thereof showed signs of abnormal neurogenesis and synaptogenesis. The neuronal phenotype could be normalized by the treatment with insulin-like growth factor 1 (IGF-1), a drug in clinical trials for ASD. ^[@ref23]^ The same drug was also beneficial in an iPS cell model harboring a disruption of the cation channel *TRPC6* . In this model, impaired neuronal development, morphology, and function were observed, which was partially rescued with IGF-1 and hyperforin, the major active component of St John's wort. ^[@ref24]^  

Next to the idiopathic variants, several genetically defined syndromes exist, which clinically present with similarities to the idiopathic ADS. These include Rett syndrome (alterations in the *MECP2* or *CDKL5* gene), Williams-Beuren syndrome (deletion on chromosome 7q11.23), Fragile X syndrome (expansion of a CGG triplet repeat in the *FRM1* gene) or Timothy syndrome (mutations in the *CACNA1C gene* encoding the calcium channel Cav1.2 α subunit). The neuronal phenotypes of Rett syndrome have been characterized in iPS cells derived from patients harboring mutations in the *MECP2* and *CDKL5* genes. Indeed, neurons derived from Rett patients exhibited a decreased number of excitatory synapses, a reduction in spine densities, a smaller soma size, and electrophysiological defects, ^[@ref7]^ phenotypes also replicated in subsequent studies. ^[@ref25]^ , ^[@ref26]^ Increasing *MECP2* by gentamycin, a drug facilitating ribosomal read-through of premature stop codons in mutant *MECP2* as well as IGF-1 were able to increase the number of glutamatergic synapses in this model. ^[@ref7]^  

Interestingly, *MECP2* mutant astrocytes were also shown to actively contribute to the morphological and functional deficits of wild-type neurons, indicating a non-cell autonomous mode of action in the disease pathogenesis. Again, IGF1 or a peptide containing the first three amino acids of IGF1 were able to partially rescue the observed alterations in that model. ^[@ref27]^ Mechanistically, pharmacological IGF1 treatment was demonstrated to be linked to an increased expression of the neuron-specific *K* ^+^ *-Cl* ^−^ *cotransporter2 (KCC2)* , a downstream target of *MECP2* and dysregulated in Rett syndrome-specific iPS cell-derived neurons. As a consequence, the developmental shift in function of the neurotransmitter GABA from excitation to inhibition which was delayed in Rett neurons was rescued towards the time course found in control iPS cell-derived neurons. ^[@ref28]^ In Timothy syndrome iPS cell-derived neurons, Pasca and coworkers found that defects in calcium signaling and activity-dependent gene expression. They also identified abnormal expression of tyrosine hydroxylase, a phenotype which could be reverted by the atypical L-type channel blocker roscovitine. ^[@ref29]^ With respect to Fragile X syndrome, a straightforward approach is to identify drugs reactivating the expression of the otherwise silenced *FMR1* gene. Using iPS cell-derived neurons, Bar Nur and colleagues investigated selected Food and Drug Administration (FDA)-approved drugs including the histone deacetylase inhibitor trichostatin-A (TSA) and the demethylating agents 5-azacytidine (5-azaC). They found that 5-azaC, but not TSA, upregulated *FRM1* expression, even though concentrations used were beyond physiological levels. ^[@ref30]^  

Mood disorders 
===============

Mood disorders are characterized by recurrent fluctuations in mood state that can lead to a dramatic reduction of the quality of life. Unipolar or major depression (MD) is the most common mood disorder and has been predicted to become the first cause of disability by 2030. ^[@ref31]^ While several factors contribute to the onset of MD, the serotonergic system seems to play a crucial role in the underpinning molecular alteration. Consequently, the majority of the drugs prescribed to depressed patients modulate the serotonergic system by increasing the synaptic availability of the monoamine or by interfering with the activity of the serotonergic receptors. Citalopram, a selective serotonin reuptake inhibitor (SSRI) has been applied to human iPS cell-derived serotoninergic neurons and serotoninergic neurons generated by direct cell conversion. All studies demonstrated elevated extracellular serotonin levels following SSRI treatment of the neurons. ^[@ref32]^ - ^[@ref34]^ Mood swings from mania to depression are characteristic for bipolar disorder (BPD), another disease from the mood disorder spectrum. BPD affects more than 1% of the general population, and is thus among the leading causes of disability in young adults. ^[@ref35]^ Lithium is currently the best-characterized drug for the treatment of BPD, even though not all patients respond to lithium administration. In line with this, lithium was shown to be effective in rescuing some of the defects identified in iPS cell-derived cultures from BPD patients including calcium transients, ^[@ref36]^ adhesion, ^[@ref37]^ progenitor proliferation, ^[@ref38]^ excitability, ^[@ref39]^ , ^[@ref40]^ or altered ratios of active/inactive modulators of dendritic spine formation. ^[@ref41]^ Interestingly, clinical response of patients to lithium strongly correlated to the in vitro response with respect to the "hyperexcitability phenotype" observed in iPS cell models allowing predictions in both directions---from the patient to the in-vitro model and vice versa. ^[@ref39]^ , ^[@ref40]^  

Cerebral organoids: 3D models of psychiatric disease 
=====================================================

Considering that many of the identified cellular phenotypes associated with psychiatric disorders are connected to defects in progenitor proliferation, cellular migration, or neuronal morphology and synapse formation, cerebral organoids are attractive models to investigate the extent to which these alterations result in architectonical or structural impairments in 3D. In recent years, cerebral organoids have successfully been applied to studying ASD and SCZ-related pathologic phenotypes (for an overview see *Table I* ). In the first reported study from 2015, the authors investigated the structure and the transcriptomic profile of telencephalic organoids derived from probands with idiopathic ASD, compared with unaffected first-degree family members. They found an imbalance in the production of excitatory and inhibitory neurons caused by an accelerated cell cycle in the GABAergic neuronal lineage. ^[@ref42]^ Another study related to ASD showed that cerebral organoids generated from iPS cells heterozygous for the *chromodomain helicase DNA-binding protein 8 (CHD8)* gene have altered transcriptomic signatures mainly related to neurogenesis, neuronal differentiation, forebrain development, Wnt/β-catenin signaling, and axonal guidance. ^[@ref43]^ The authors found a marked upregulation of *TCF4* , a candidate gene potentially involved in other psychiatric disorders such as SCZ and BP. More recently, cortical organoids were derived from a selected cohort of ASD patients with macrocephaly. The organoids showed increased thickness of the cortical plate and aberrant complex neurite outgrowth of newborn neurons, a phenotype in line with the increased brain size of the patients. The authors claimed that the abnormal growth acceleration in ASD organoids is ascribable to the alteration of specific gene modules and the consequent altered trajectory during the early phases of cortical development. This elegant approach confirmed the involvement of neural precursors in ASD-related structural alterations. ^[@ref44]^ Defects in neurogenesis and neuronal differentiation were also observed in cerebral organoids derived from patients harboring mutations in the *MECP2* . Specifically, organoids showed structural abnormalities in ventricular area and radial thickness, together with increased cellular proliferation and decreased neuronal maturation. This study pointed out the role played by two specific miRNAs (miR-199 and miR-214) in the altered phenotype, suggesting a new molecular mechanism downstream of *MECP2* mutations. ^[@ref45]^ A study focusing on mutations of *DISC-1* (disrupted-in-schizophrenia 1) and its interaction with Ndel1, a protein involved in cell cycle control, showed that the *DISC-1* /Ndel1 interaction is fundamental for the correct regulation of mitosis in radial glial cells both in iPS cell mutant for *DISC-1* and SCZ patient-derived telencephalic organoids. ^[@ref17]^ Together, these are exciting examples demonstrating the power of the organoid technology and pave the way for future studies implementing psychopharmacology. 

From candidate pharmacology to drug discovery 
==============================================

Even though most studies so far concentrated on few candidate drugs, the feasibility of translating iPS cell models to cellular drug screening has been demonstrated. Kauffmann and coworkers used fragile X iPS cell-derived neural precursors to screen for the reactivation of the silenced *FMR1* testing a total of 50 000 compounds. They identified a small set of compounds showing a significant increase in *FMR1* expression. ^[@ref46]^ Another study set up a sensitive fluorescence resonance energy transfer-based assay for the determination of FMR1 levels, testing more than 5000 compounds, among those about 4000 FDA-approved drugs. Six drugs showed an increase in *FMR1* expression, even though none of the tested drugs induced *FMR1* to clinically relevant levels. ^[@ref47]^ A more recent publication demonstrates how iPS cells could be used to predict drug response in case of psychiatric disorders. Comparing transcriptional profiles of cancer cell lines, neural progenitors from healthy controls and neural progenitor cell lines from patients with SCZ exposed to a set of 135 drugs, the authors identified several drugs reversing post-mortem SCZ-associated transcriptomic signatures in a cell-type and disease-specific manner. ^[@ref48]^ Such examples nicely demonstrate how to incorporate patient-derived material with idiosyncratic genetic compositions into larger, OMICS-based screening approaches and thus may help to combine genetics, cell-based molecular profiling, and pharmacology. ^[@ref49]^ It is important to mention that with modern gene editing approaches, iPS cells are also amenable to large-scale genetic manipulation including iCRISPR---a platform which allows rapid, multiplexable, and inducible genome editing in human PSC raising the possibility to introduce multiple modifications at different loci simultaneously in the same cell. ^[@ref50]^ For the cerebral organoid cultures, several further optimization steps are required to broadly and effectively include this system in psychopharmacology and drug discovery. One important issue is the question of scalability. Unlike 2D cultures, cerebral organoids still represent heterogeneous cultures with considerable variation within and across batches. The development of improved culture conditions including defined extracellular matrices might facilitate the generation of more reproducible organoid systems (reviewed in ref 51) The issue of scalability is also relevant for the phenotypic analysis of organoids. Due to their complex and heterogeneous 3D nature, time-consuming processing procedures such as sectioning and staining of single slides are still standard. Advanced clearing protocols might help to develop standardized high-throughput imaging analysis protocols and single-cell profiling might help bypass issues with respect to cellular heterogeneity. For functional profiling, organoids with mature neuronal circuits of consistent quality have to be developed. At some point, increasing the complexity by including non-neuroectodermal populations such as microglial cells ^[@ref52]^ or a vasculature ^[@ref53]^ , ^[@ref54]^ might be necessary to model the complex interaction of different cell populations in the response to pharmacological intervention.  

Reconstructing the translational drug discovery pipeline in psychopharmacology 
===============================================================================

Central nervous system (CNS) drug development is considered risky, especially because so many promising CNS drugs failed in late-stage clinical trials, after significant investments had been made. ^[@ref55]^ Since 1975, only 33 drugs have been registered for psychiatry, ^[@ref56]^ and the pharmaceutical industry is constantly cutting down research into psychiatric drugs, ^[@ref57]^ , ^[@ref58]^ implying that the drug development pipeline for psychiatric drugs is currently running dry. In the classical pipeline, molecular targets for drug discovery are mostly defined on transformed cell lines and/or transgenic mice harboring or overexpressing one of the few CNVs or mutations with high penetrance. Such models insufficiently reflect the majority of psychiatric patients and the specific situation in the human brain leading to a plethora of false-positive results which are processed via the entire drug discovery pipeline before eventually proven ineffective in clinical trials. One reason for the ineffectiveness of drug discovery in psychiatry might be due to the classification of psychiatric spectrum disorders according to clinical symptoms ignoring the recent developments towards a stratification and classification of patients according to specific domain criteria (also called Research Domain Criteria \[RDoC\]). ^[@ref59]^ Molecular studies and functional assessment of psychiatric patients strongly suggest breaking with conventional clinical classifications and stratifying patients into specific research domain criteria-defined "biotypes." ^[@ref60]^ Considering the high costs of failures in the late stages of drug discovery, it will be important to dramatically reduce the false-positive results in early stages of the pipeline. In this context and as outlined above, iPS cell-based models will develop towards a pivotal role in the patient stratification and classification processes as well as target identification and validation, eventually leading to a more effective drug discovery pipeline. The refined drug discovery pipeline including iPS cell-based 2D models and cerebral organoids is outlined in *Figure 1* . In such a scenario, the classification of patients into heterogeneous collectives by clinical manifestation is refined by applying research domain criteria from unbiased clinical testing (such as MRI and functional studies). IPS cell-based models (2D and organoids) investigating molecular and functional signatures on a cellular or network level should lead to a further refinement into "molecular target biotypes." Performing high content screens directly in iPS cell-derived neural cultures from such biotype-stratified individuals should minimize artefacts due to molecular heterogeneity and an inadequate cellular physiology, and should at the same time provide information about toxicology of a certain compound to predict the insurgence of side effects in authentic human brain cells. Secondary screens based on complex cellular models such as cerebral organoids should further reduce the number of false-positive hits processed into the subsequent steps of drug discovery. Thus, in such a refined pipeline, iPS cell-based systems will streamline drug development by biotype stratification, target identification and validation eventually leading to precise "mechanistic" pharmacological intervention and accordingly to the development of the so-called "precision psychiatry." ^[@ref4]^  

Conclusion 
===========

IPS cell-based in vitro models are promising tools to study previously inaccessible aspects of human brain development and neuropsychiatric diseases. It is, however, important to note that iPSC-derived brain models have their limitations with respect to reproducing the in vivo situation of the human brain. In this context major restrictions are the lack of maturity and limitations in the cellular composition (these models do not contain blood vesicles or immune cells). We should also consider that each iPSC clone represents one epigenetic variant of the given genetic background and thus results need to be reproduced across several clones and individuals. Protocol improvements that enable greater maturation and cellular diversity combined with advanced readout techniques including high-throughput single cell OMICs and whole-organ imaging will enable to investigate previously experimentally inaccessible processes disturbed in neuropsychiatric disease and will by that be of great use for the translational drug discovery pipeline. 

DISEASESAMPLE DETAILSGENETIC ALTERATIONSCELL TYPEPHENOTYPEPHARMACOLOGICAL TREATMENTDOI2D MODELSSCZ2 patients (1 male; 1 female)DISC-1 mutationiPSCNot characterized. First iPSC generated from SCZ patients.None10.1038/ mp.2011.134 patients (3 males; 1 females)Different SCZ-linked copy- number variantsNPC, neuronsReduced connectivity, reduced neurite outgrowth, reduced synaptic protein levels.Loxapine increases neuronal connectivity; Clozapine, olanzapine, risperidone, Thiorizadine have no effect.10.1038/ nature099151 patient (woman)Not specified - CLZ resistantNCPPatient-derived NPCs show alterations in oxygen metabolism and generation of ROS.Valproate normalizes the levels of ROS.10.3727/ 096368911X6009573patients (2 males; 1 female)Not specifiedNPC, Glut and DA neuronsImpaired maturation of DA neurons; decreased levels of synapsin-1 and PSD-95 in Glut neurons. The phenotypes were associated with mitochondrial dysfunction.None10.1038/ mp.2013.674 patients (3 males; 1 females)Different SCZ-linked copy- number variantsNeuronsIncreased secretion of dopamine, norepinephrine, and epinephrine after stimulation and increased levels of tyrosine hydroxylase when compared to control neurons.None10.1016/ j.stemcr.2014.08.0011 patient (woman)Not specified - CLZ resistantNCPPatient derived neurospheres show increased levels of K+ and Zn+ when compared to control cells.Valproate reverts the K+ and ZN+ unbalance.10.1016/ j.schres.2014.02.0074 patients (3 males; 1 females)Different SCZ-linked copy- number variantsHippocampal DG granule neuronsDeficits in DG granule neurons generation; decrease of NEUROD1, PROX1, and TBR1; reduced neuronal activity; reduced spontaneous neurotransmitter release.None10.1016/ j.stemcr.2014.01.0093 patients (2 males; 1 female)15q11.2 microdeletionNPCCYFIP1 haplosufficiency; deficits in adherens  junctions and apical polarity.None10.1016/ j.stem.2014.05.0032 patients (1 male; 1 female)DISC-1 mutationFB NPCs and neuronsImpairment of synaptic vesicle release; functional synaptic transmission deficits; alteration at transcriptomic level of genes related to synaptic activity.None10.1038/ nature137164 patients (3 males; 1 female)Different SCZ-linked copy- number variantsFB NPCAberrant cell migration; changes in cellular adhesion and oxidative stress pathways; transcriptional  signatures related to SCZ pathophysiology.Clozapine and loxapine did not  rescue the defects in cell migration.10.1038/ mp.2014.221 patient (sex not specified)15q11.2 deletioniPSC, neuronsAltered dendritic morphology in iPSC-derived  neurons.None10.1159/ 0004309161 patient (female); 1 neurotypical carrier (male)Heterozygous intragenic  CNTNAP2 deletionsFB and Glut neurons, OPCCharacterization of CNTNAP2 structural deletions  in iPSC, neurons and OPC; Impaired neuronal  migration in patient-derived neurospheres.None10.1038/ npjschz.2015.194 patients (3 males; 1 female)Different SCZ-linked copy- number variantsFB NPCPerturbed WNT signaling.None10.1016/ j.biopsych.2014.12.0282D MODELSSCZIsogenic cell linesDISC-1NPC, neuronsOveractivation of WNT signaling and altered  expression of FOXG1 and TBR2.None10.1016/j.celrep.2015.07.0616 patients (3 males; 3 females)22q11.2 microdeletionsNeurons  (50% Glut; 50% GABA)Patient-derived neurons recapitulate the miRNA expression patterns expected from 22q11.2  haploinsufficiency and are comparable to the data obtained from autoptic specimens.None10.1371/ journal.pone.01323874 patients (3 males; 1 females)Different SCZ-linked copy- number variantsNPCmiR-19 is upregulated in and represent a key factor regulating the expression of genes associated with abnormal migrationNone10.1080/ 23262133.2016.12518731 patient (female) CLZ responder 1 patient (female) CLZ non-responderNot specified - Monozygotic twinsGlut neuronsAnalysis of CLZ transcriptional impact on neurons derived from responder and resistant patients.  The main differences in gene expression were related to homophilic adhesion molecules (CDH8, DSC3 and protocadherins).Clozapine10.1016/ j.schres.2016.10.0124 patients (3 males; 1 female)Different SCZ-linked copy- number variantsFB neuronsDifferential effect of activity--dependent changes  of gene expression in patient-derived NPCs.None10.1001/ jamapsychiatry.2016.2575Two cohorts: SZ1 4 patients  (3 males; 1 females);  SZ2 10 COS patients  (6 males; 4 females)Different SCZ-linked copy- number variantsFB NPCImpaired migration associated to miR-19 decrease.None10.1016/ j.celrep.2016.03.0902 patients (2 females)22q11.2 deletionNeurospheresSignificant reduction of neurosphere size,  neural differentiation efficiency, neurite outgrowth, cellular migration and the neurogenic-to-gliogenic competence ratio.None10.1038/ tp.2016.2061 patient (male)Not specifiediPSCNot characterized. Derivation of an iPSC line from  a CLZ-resistant schizophrenic patient.None10.1016 /j.scr.2016.11.0052 patients (1 male; 1 female)DISC-1 deletionNSCUpregulation of miR-219 and downregulation of TLX expression in NSCs derived from SCZ patient and DISC1-mutant isogenic iPSCs. SCZ NSCs exhibit reduced cell proliferation and increased neuronal differentiation.None10.1038/ ncomms109651 patient (female);  1 neurotypical carrier (male)Heterozygous intragenic  CNTNAP2 deletionsFB and Glut neuronsIncreased synaptic activity in the CNTNAP2 deletion carriers.None10.1016/ j.brainres.2015.11.0094 patients (3 males; 1 female)Different SCZ-linked copy- number variantsNCCSeveral common molecular pathways dysregulated among the unrelated cases of SCZ analyzed. nFGFR1 signaling enlightened as a potential common altered mechanism.None10.1016/ j.schres.2016.12.0122D MODELSSCZ5 patients  (2 males; 3 females)Not specifiedGPC, astrocytesWhen transplanted into hypomyelinated mice, patient-derived GPC prematurely migrate into the cortex, leading to reduced white matter expansion and hypomyelination relative to controls. Animals show reduced pre-pulse inhibition and abnormal behavior.None10.1186/ s13229-015-0048-612 patients (7 males; 5 females)Different SCZ-linked copy- number variantsNPCIn silico drug-screening approach to investigate  the transcriptomic effect of several drugs on  patient-derived NPC.135 different drugs.10.1038/ s41467-018-06515-44 patients  (3 males; 1 females)Different SCZ-linked copy- number variantsHippocampal neuronsGeneration of DG and CA3 neurons from SCZ  patients. DG-CA3 co-culture revealed a reduced spontaneous activity and neural network  connectivity of patient-derived neurons.None10.1016/ j.stem.2018.04.009Two cohorts: SZ1 4 patients  (3 males; 1 females);  SZ2 9 COS patients  (6 males; 3 females)Different SCZ-linked copy- number variantsFB and excitatory neuronsIncreased STEP61 activity in iPSC-derived neurons from schizophrenic patients caused increased  phosphorylation of GLUN2B. Alterations in  GLUN2A/GLUN2B ratio is a proxy of decreased  synaptic strength.Clozapine, loxapine increase STEP61 phosphorylation and normalizes the molecular alterations observed.10.1038/ s41593-018-0313-z14 patients  (males - clozapine treatment)Not specifiedCortical interneuronsDownregulation of protocadherin gene expression. Defects in arborization. Decreased number of  inhibitory synapses after in vivo transplantation.PKC inhibitor corrects arborization impairments in vitro.10.1038/ s41593-018-0313-zIdiopatic ASD 1 patient  (male)TRCP mutationNPC, neuronsAberrant Ca++ signaling; decreased spine density, neurite length and axonal outgrowth; altered  expression of SYNAPSIN-1 and PSD-95.IGF-1 and hyperforin normalized the deficits observed.10.1038/ mp.2014.141Healthy subjectCRISPR-Cas mutation on  CHD8 geneNPC, neuronsAlteration in molecular pathways related to neurodevelopment and genes associated to ASD or  schizophrenia in mutated NPC and neurons.None10.1186/ s13229-015-0048-63 patients  (males)Not specifiedNeuronsDecreased frequency of spontaneous EPSC and  decreased Na+ and K+ voltage gated currents.  Transcriptomic analysis revealed dysregulated  processes in synaptic transmission and other pathways known to be altered in ASD.None10.1007/ s12035-016-9961-88 patients (sex not specified)Not specifiedNPC, neuronsNPC show increased cellular proliferation correlated with brain size of the donors and associated with the increased activity of the ß-catenin/BRN2 cascade; neurons display abnormal neurogenesis, reduced synaptogenesis and functional defects in neuronal networks.IGF-1 corrects the deficits related to neurogenesis and synaptogenesis.10.1038/ mp.2016.952D MODELSIdiopatic ASD6 patients  (males)Not specifiedCortical neuronsConvergent molecular traits in idiopathic ASD affect synaptic development and function, metabolism, and cellular molecular interactions involving the cytoskeletal matrix; altered neuronal migration  and electrophysiological activity.None10.1038/ s41598-018-26495-1Rett  syndrome1 patient  (female)MECP2 missense mutationiPSCFirst study to derive iPSC from a patient affected  by Rett Syndrome.None10.1038/ nmeth.13254 patients  (females)Different MECP2 mutationsNeuronsFewer synapses, reduced spine density, smaller  soma size, altered calcium signaling and  electrophysiological defects.IGF-1 and gentamicin rescued the altered phenotype.10.1016/ j.cell.2010.10.0161 patient  (female)1155del32 Frameshift  mutation on MECP2NPC, neuronsNPC carrying MeCP2 mutations have increased  susceptibility for L1 retrotransposition.None10.1186/ s13229-015-0048-65 patients  (females)Different MECP2 mutationsiPSC, neuronsDue to chromosome X reactivation authors obtained biallelic and monoallelic mutants. Patient-derived iPSC show defects in neuronal maturation.None10.1073/ pnas.10189791082 patients  (females)CDKL5 mutationsNeuronsAberrant spine morphology, as observed in the in vivo modelNone10.1038/ ncb25663 patients  (females)Different MECP2 mutationsAstrocytes, GABA  interneuronsMouse hippocampal neurons show decreased soma size, neurite length and number of terminal ends when cocultured with or when exposed to astrocyte conditioned media. Similar morphological effects were observed when astrocytes were co-cultured with wild-type or mutated iPSC-derived interneurons. The effects observed were independent from the different mutations carried by the patients.IGF-1 and GPE (peptide containing the first 3 AA of IGF-1) have beneficial effects on the interneuron- astrocyte cocultures.10.1093/ hmg/ddu0081 patient  (female)MECP2e1 mutation  (deletion on exon1)iPSC, cortical neuronsDefects in soma size and reduced dendritic complexity. Impaired neuronal function was confirmed by alteration of action potential, channel function and synaptic responsiveness.None10.1016/ j.nbd.2015.01.0011 patient  (male)MECP2 mutationNeuronsDecreased levels of KCC2, with consequent  impaired GABA functional switch from excitation  to inhibition.IGF-1 normalizes KCC2 levels and the altered phenotype.10.1073/ pnas.1524013113Williams syndrome 1 patient  (sex not specified)Different chromosome band 7q11.23 mutationsCortical neuronsAlterations in action potentials and transcriptional dysregulations related to neurotransmitter receptor activity, synaptic assembly, and potassium channel complexes.None10.1016/ j.nbd.2015.01.0012D MODELSWilliams syndrome5 patients  (3 males; 2 females)Different chromosome band 7q11.23 mutations (1 male patient with partial deletion)NPC and cortical neuronsNPC have increased doubling time and increased apoptosis, associated to FRIZZLED9 dysfunctions. Cortical neurons show longer total dendrites, increased number of spines and synapses and altered connectivity.None10.1038/ nature19067Timothy syndrome 2 patients  (sex not specified)CACNA1C mutationCortical neuronsDefects in Ca++ signaling and activity-dependent gene expression; altered neuronal differentiation; increase release of norepinephrine and dopamine; increased levels of TH.Roscovitine normalizes the levels of TH.10.1038/ nm.2576Fragile X syndrome 3 patients  (males)FMR1 mutationiPSCGeneration of iPSC lines from FXS patients and investigation of FMR1 inactivation after cell  reprogramming.None10.1016/ j.stem.2010.04.0053 patients  (males)FMR1 mutationiPSC and neuronsFewer and shorter neurites.None10.1371/ journal.pone.0026203Not specifiedFMR1 mutationiPSC, neuronsAnalysis of two chromatin remodeling drugs to  reactivate FMR1 expression in iPSC and neurons.5-azacytidine increases the levels of FMR1 in iPSC and neurons, while Trichostatin-A has no effect.10.1093/ jmcb/mjs0073 patients (males)FMR1 mutationFB neuronsDefective neurite initiation and extension.None10.1089/scd.2014.00301 patient  (sex not specified)FMR1 mutationNPCEstablishment of a high-content imaging assay  to run a large-scale phenotypic screen aimed to identify compounds that reactivate the silenced FMR1 gene.HTS of 50000 compounds.10.1177/ 10870571155882871 patient  (sex not specified)FMR1 mutationNPCEstablishment of a sensitive fluorescence resonance energy transfer-based assay for the determination of FMRP levels in FXS patient cells.HTS of 4000 FDA approved  compounds.10.5966/ sctm.2014-0278BPD3 patients  (sex not specified)Not specifiediPSC, neuronsExpression of transcripts for membrane bound  receptors and ion channels was significantly  increased in BP-derived neurons. BD- derived  neurons expressed genes involved in the  differentiation into ventral regions.Lithium as dorsalizing agent.  Treatment significantly decrease Ca++ transient and wave amplitude.10.1038/ tp.2014.1212 patients  (sex not specified)Not specifiediNLCThe authors developed an automated imaging system to detect cellular differences between cells derived from neuronal cells derived from LiNR patients.Lithium10.1038/ nature155262D MODELSBPD1 patient  (male)Not specifiedNPC and neuronsUpregulation of miR-34a could affect the expression of multiple genes associated with BD. Increase of miR-34 impairs neuronal differentiation, expression of synaptic proteins and neuronal morphology of NPC.None10.1038/ mp.2014.1764 patients  (2 males; 2 females)Not specifiediPSC, NPC and neuronsGene ontology pathway analyses revealed  dysregulations of RNA metabolism, cilium assembly, WNT signaling and vesicular trafficking in late stage neurons.None10.1038/ mp.2014.1762 patients  (2 males)Not specifiedNPCDifferential expression of genes involved in regulating proliferation, neuronal differentiation and calcium signaling in CXCR4+ NPC.Glycogen synthase kinase 3 inhibitor normalizes the deficits in cell  proliferation.10.1038/ mp.2015.73 LiR (males);  3 LiNR (males)Not specifiedHippocampal DG granule neuronsNeurons show altered expression of genes related to mitochondrial activity, calcium signaling, and neuronal excitability. BD neurons show a hyperexcitability phenotype.Lithium corrects the hyperexcitability and mitochondrial dysregulations only in LiR neurons.10.1038/ nature155267 LiR (males); 3 LiNR (males)Not specifiedNPC, neuronsCRMP2 is identified as central mediator of lithium mechanism of action. Inactive/active CRMP2 ratio  is altered only in LIR-derived neurons and is  normalized by lithium treatment. On the contrary, LiNR-derived neurons show no abnormalities in CRMP2 inactive status.Lithium10.1073/ pnas.17001111146 patients  (3 males; 3 females)Not specifiediPSC, NPCThe transcriptomic analysis shows increased expression of molecules related to neuroinflammation (e.g. NLRP2; TREM1 pathway), pointing out a critical role in the early pathological mechanisms of BD.None10.1038/ tp.2016.2843 LiR (males);  3 LiNR (males)Not specifiedHippocampal DG granule neuronsHyperexcitability when compared to controls.  LiR and LiNR-derived neurons share excitability as common phenotype but show several electrophysiological differences that can be successfully used  to predict pharmacological responsiveness.Lithium corrects the hyperexcitability of LiR neurons.10.1038/ mp.2016.2601 healthy controlNot specifiedNPC, neuronsHigh-throughput screening of WNT/ß-catenin pathway modulators in NPC transfected with a WNT signaling reporter construct.1500 FDA approved compounds.10.1177/ 1087057112456876MDHealthy subjectsNot specifiedSerotonergic neuronsDirect conversion of human fibroblasts to  serotonergic neurons.Citalopram10.1038/ mp.2015.161Healthy subjectsNot specifiedSerotonergic neuronsDirect conversion of human fibroblasts to  serotonergic neurons.Citalopram10.1038/ mp.2015.1012D MODELSMDHealthy subjectsNot specifiedSerotonergic neuronsReprogramming of iPSC into serotonergic neurons.Citalopram, tramadol10.1038/mp.2015.7Organoid ModelsSCZ2 patients  (males)DISC-1 mutationForebrain organoidDISC1/Ndel1 interaction in regulating mitosis of  RGC; delayed cell-cycle progression during mitosis  of RGC in human forebrain organoids bearing  DISC-1 mutation.None10.1177/ 1087057112456876Isogenic cell linesDISC-1 mutationCerebral organoidDISC-1 mutation alters the morphology of cerebral organoids, increasing the number of small and disorganized rosettes and inducing a decrease of ventricle-like structures; WNT antagonist restore the observed phenotype.None10.1038/ s41398-018-0122-x3 patients  (2 males; 1 females)Not specifiedCerebral organoidPatient-derived organoids show abnormal  subcortical neurogenesis and increased, premature neuronal generation; structural and molecular  alterations observed were correlated to nuclear FGFR1 decrease.None10.1038/ s41398-018-0122-xASD4 patients  (males)Not specifiedTelencephalic organoidPerturbed transcriptomic signatures in ASD  organoids related to cellular proliferation,  neuronal differentiation and process outgrowth, and synaptic transmission; increase in Synapsin-1; FOXG1 interference attenuates the phenotype.None10.1016/ j.cell.2015.06.034Healthy subjectCRISPR-CAS9 mutation of CDH8Cerebral organoidUpregulation of TCF4; altered transcriptomic  signature in mutated organoids in pathways  related to neurogenesis, neuronal differentiation, forebrain development, WNT/β-catenin signaling, and axonal guidance.None10.1186/ s13229-017-0124-12 patients  (females)MECP2 mutationCerebral organoidMeCP2 deficiency in monolayer and 3D cultures causes defective neurogenesis and neuronal  differentiation potentially associated to miR-199.None10.1038/ mp.2017.868 patients  (males)Not specifiedForebrain organoidOrganoids derived from ASD patients show  increased thickness of the cortical plate and aberrant complex neurite outgrowth of newborn neurons. This phenotype is in line with the increased brain size of the patients and confirms the data obtained with NPC cultures.None10.1038/ s41593-018-0295-x00000
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